Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureCsaba P. Kovesdy
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Semaglutide for chronic kidney disease in type 2 diabetes
10.1056/nejmc2410532 · 2024
Glucagon-like peptide-1 receptor agonist use and risks of hospitalization and mortality in patients with end-stage kidney disease
2026
Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease
10.1001/jamanetworkopen.2022.1169 · 2022
GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis
10.2215/cjn.0000000750 · 2025
Evaluating medication effects outside of clinical trials: new-user designs
10.1093/aje/kwg231 · 2003
The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application
10.1007/s40471-015-0053-5 · 2015
Global prevalence of protein-energy wasting in kidney disease: a meta-analysis of contemporary observational studies from the International Society of Renal Nutrition and Metabolism
10.1053/j.jrn.2018.08.006 · 2018
Bariatric surgery and kidney health
10.1681/asn.2018020176 · 2018
Obesity and metabolic health in CKD
10.2215/cjn.0000000704 · 2025
Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia
10.1177/11795514211051697 · 2021
No additional external references are available.